RARE

#1581
Ultragenyx Pharmaceutical Inc. - Common Stock
23.9 4 USD
+2.92%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
23.94
23.94
Yıllık Aralık
18.29
42.37
Günlük Değişim
+2.92%
Aylık Değişim
-2.17%
6 Aylık Değişim
-29.98%
Yıllık Değişim
-31.34%
Önceki Kapanış
23.2 6
Open
23.9 4
Düşük
23.9 4
High
23.9 4
Hacim
142
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler
Çeyreklik Yıllık
  • Market Capitalization 2.36 B
  • Employee 1 371
  • Founded 2010
  • CEO Emil Kakkis
  • Website www.ultragenyx.com
  • Headquarter Delaware, United States
  • FIGI BBG001RWPDW6
  • Industry Biyoteknoloji
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
-3.95
Fiyat/satışlar oranı
3.37

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.

Haberler